Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Parkinsonism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    258 result(s) found for: Parkinsonism. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-000364-21 Sponsor Protocol Number: PI1102031 Start Date*: 2012-11-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomédica
    Full Title: FDDNP-PET FOR IN VIVO DIAGNOSIS OF TAUOPATHY IN UNCLASSIFIABLE PARKINSONISM
    Medical condition: Atypical Parkinsonism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10034010 Parkinsonism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002216-25 Sponsor Protocol Number: PDT409 Start Date*: 2006-06-26
    Sponsor Name:Amersham Health, S.A. (filial de GE Healthcare Ltd)
    Full Title: Ensayo en fase 4 multicéntrico, aleatorizado, abierto y comparativo para evaluar las modificaciones en el manejo clínico después de una tomografía con DaTSCAN en sujetos con parkinsonismo clínicame...
    Medical condition: The subjects included in this trial will have clinically uncertain parkinsonism in a general neurologist setting.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000801-30 Sponsor Protocol Number: E2007-G000-318 Start Date*: 2007-08-01
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects with Motor...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) PL (Completed) FR (Completed) ES (Completed) IT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002339-26 Sponsor Protocol Number: E2007-G000-303 Start Date*: 2006-10-05
    Sponsor Name:Eisai Limited
    Full Title: A Multi-centre, Open Label Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Patients with Motor ...
    Medical condition: Levodopa treated Parkinson's disease patients with motor fluctuations.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) CZ (Completed) HU (Completed) BE (Completed) SE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) DE (Completed) ES (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003045-26 Sponsor Protocol Number: Pearl-PD Start Date*: 2015-10-23
    Sponsor Name:Umeå University Hospital
    Full Title: [18F] FE-PE2I PET/CT study of Dopamine Transporters in Early Parkinsonian disease.
    Medical condition: Patients with newly clinically diagnosed untreated idiopathic parkinsonism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004290-19 Sponsor Protocol Number: SP873 Start Date*: 2006-01-25
    Sponsor Name:Schwarz Biosciences GmbH
    Full Title: A double-blind, placebo-controlled, parallel group, proof of concept trial to assess the tolerabiltiy, safety and efficacy of rotigotine nasal spray for the acute treatment of 'off' symptoms in sub...
    Medical condition: advanced-stage, idiopathic Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002467-27 Sponsor Protocol Number: 2007 Neuro 12 Start Date*: 2008-01-24
    Sponsor Name:Salford Royal NHS Foundation Trust
    Full Title: Antidyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients with Parkinson's Disease and Levodopa-Induced Dyskinesias
    Medical condition: Patients with idiopathic Parkinson's disease and levodopa-induced dyskinesias
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013916 Dyskinesia PT
    13.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    13.1 10029205 - Nervous system disorders 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017182-38 Sponsor Protocol Number: IPX066-B09-03 Start Date*: 2010-05-14
    Sponsor Name:Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
    Full Title: An Open-Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects with Parkinson´s Disease
    Medical condition: Idiopathic Parkinson´s disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) DE (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-001416-42 Sponsor Protocol Number: TVP-1012/500 Start Date*: 2005-09-15
    Sponsor Name:Teva Pharmaceuticals Industries LtD
    Full Title: A Multicenter, Double-Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson’s Disease Subjects
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    7.1 10061536 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) IT (Completed) ES (Completed) AT (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005234-39 Sponsor Protocol Number: 2939111 Start Date*: 2005-05-27
    Sponsor Name:Orion Corporation, ORION PHARMA, Finland
    Full Title: Multicentre, randomised, double-blind study to compare Stalevo® to levodopa/carbidopa in patients with Parkinson's disease experiencing symptoms of early wearing-off
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061536 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DK (Completed) FI (Completed) IE (Completed) DE (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2014-002697-37 Sponsor Protocol Number: 14/0382 Start Date*: 2015-04-15
    Sponsor Name:University College London
    Full Title: Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease
    Medical condition: Parkinson's Disease Nocturia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    17.1 10029205 - Nervous system disorders 10034007 Parkinson's disease NOS LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011541-24 Sponsor Protocol Number: TVP-1012/501 Start Date*: 2009-10-09
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects who Participated in the ADAGIO Study
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) HU (Completed) FR (Completed) ES (Completed) IT (Completed) DE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004795-19 Sponsor Protocol Number: 120824001 Start Date*: 2013-03-12
    Sponsor Name:Folktandvården Västra Götaland
    Full Title: Utilisation of botulinum toxin type A on masticatory muscel hyperactivity in CP - a randomized, controlled study.
    Medical condition: Masticatory muscle hyperactivity/bruxism in patients with Cerebral Palsy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028037 Movement disorders (incl parkinsonism) HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000148-40 Sponsor Protocol Number: PDSTAT2015 Start Date*: 2015-11-09
    Sponsor Name:Plymouth Hospitals NHS Trust
    Full Title: Simvastatin as a neuroprotective treatment for Parkinson's disease: a double-blind, randomised, placebo controlled futility study in patients of moderate severity.
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    18.0 10029205 - Nervous system disorders 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-000833-12 Sponsor Protocol Number: NW-1015/015/III/2003 Start Date*: 2004-12-02
    Sponsor Name:Newron Pharmaceuticals S.p.A.
    Full Title: A phase III, double-blind, placebo-controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide, as add-on therapy, in patients ...
    Medical condition: Early idiopathic Parkinson’s disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10013113 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000835-27 Sponsor Protocol Number: NW-1015/017/III/2003 Start Date*: 2004-12-03
    Sponsor Name:NEWRON PHARMACEUTICALS
    Full Title: A phase III, double-blind, placebo-controlled, 12-month extension study to investigate the efficacy and safety of a dose range of safinamide of 50-200 mg/day, as add-on therapy in patients with ear...
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061536 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008210-38 Sponsor Protocol Number: 2008_02/0841 Start Date*: 2009-04-16
    Sponsor Name:Chru de Lille
    Full Title: Effet d’un traitement anti-glutamatergique sur les troubles de la marche avec freezing et sur l’attention dans la maladie de Parkinson: “freezing of gait and glutamate: FOGG-I”
    Medical condition: Patients ayant une maladie de Parkinson Patients à un stade évolué de la maladie avec des troubles de la marche sévères
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    9.1 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-010193-38 Sponsor Protocol Number: IPX066-B08-05 Start Date*: 2009-06-02
    Sponsor Name:IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
    Full Title: A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease
    Medical condition: Idiopathic Parkinson's disease (paralysis agitans)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2010-021394-37 Sponsor Protocol Number: SP0976 Start Date*: 2011-03-08
    Sponsor Name:UCB Pharma SA
    Full Title: MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP, PHASE IV STUDY TO ASSESS THE EFFECT OF ROTIGOTINE ON NON-MOTOR SYMPTOMS IN PATIENTS WITH IDIOPATHIC PARKINSON’S DISEASE
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) BE (Completed) CZ (Completed) SK (Completed) ES (Completed) AT (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001722-25 Sponsor Protocol Number: ZonMw80-83600-98-10226 Start Date*: 2013-08-27
    Sponsor Name:VU University Medical Center
    Full Title: Cholinesterase inhibitors to slow progression of visual hallucinations in Parkinson’s disease: a multi-center placebo-controlled trial (CHEVAL)
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA